160 related articles for article (PubMed ID: 15172086)
1. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
Agorastos T; Vaitsi V; Paschopoulos M; Vakiani A; Zournatzi-Koiou V; Saravelos H; Kostopoulou E; Constantinidis T; Dinas K; Vavilis D; Lolis D; Bontis J
Maturitas; 2004 Jun; 48(2):125-32. PubMed ID: 15172086
[TBL] [Abstract][Full Text] [Related]
2. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
[TBL] [Abstract][Full Text] [Related]
3. [GnRH agonist and add back therapy--indications, results and problems in the treatment of genital endometriosis].
Mettler L
Zentralbl Gynakol; 2003; 125(7-8):267-75. PubMed ID: 14505262
[TBL] [Abstract][Full Text] [Related]
4. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain.
Al-Azemi M; Jones G; Sirkeci F; Walters S; Houdmont M; Ledger W
BJOG; 2009 Nov; 116(12):1646-56. PubMed ID: 19735378
[TBL] [Abstract][Full Text] [Related]
5. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
6. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy.
Murray SC; Muse KN
Fertil Steril; 1997 Feb; 67(2):390-3. PubMed ID: 9022620
[TBL] [Abstract][Full Text] [Related]
7. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
Pashov AI; Tskhay VB; Ionouchene SV
Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
[TBL] [Abstract][Full Text] [Related]
8. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
Morris EP; Rymer J; Robinson J; Fogelman I
Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
[TBL] [Abstract][Full Text] [Related]
10. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up.
Pérez-Medina T; Bajo J; Folgueira G; Haya J; Ortega P
Gynecol Oncol; 1999 May; 73(2):299-304. PubMed ID: 10329050
[TBL] [Abstract][Full Text] [Related]
11. Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome.
Palomba S; Orio F; Manguso F; Russo T; Falbo A; Lombardi G; Doldo P; Zullo F
Fertil Steril; 2005 Apr; 83(4):1012-20. PubMed ID: 15820814
[TBL] [Abstract][Full Text] [Related]
12. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
[TBL] [Abstract][Full Text] [Related]
13. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices.
Perino A; Quartararo P; Catinella E; Genova G; Cittadini E
Acta Eur Fertil; 1987; 18(2):137-40. PubMed ID: 3115027
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
15. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study.
Chen JM; Gao HY; Ding Y; Yuan X; Wang Q; Li Q; Jiang GH
Chin Med J (Engl); 2015 Feb; 128(4):427-32. PubMed ID: 25673440
[TBL] [Abstract][Full Text] [Related]
17. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
Odmark IS; Carlström K; Jonsson B; Jonasson AF
Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
19. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
[TBL] [Abstract][Full Text] [Related]
20. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
